Extending the Reach of Protein Degradation Therapies

Rami Hannoush co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and how its built an atlas of tissue-specific degrader antibodies to target proteins involved in cancer, immunologic-, and neurologic-related conditions.